What the research found

This isn't a research paper—it's a narrative essay examining how peptides are entering mainstream use outside traditional healthcare channels. The piece traces the emergence of direct-to-consumer peptide platforms like Protocole, founded by someone who found conventional medicine unhelpful despite normal lab results. The backdrop is the GLP-1 boom: a drug shortage created a legal loophole allowing compounding pharmacies to produce cheaper copies, which fundamentally rewired how Americans access medications—bypassing insurers, pharmacy benefit managers, and primary care entirely. GLP-1 spending in the US grew roughly fivefold between 2018 and 2023, with projections suggesting continued explosive growth.

The essay frames peptides as the logical next frontier for this model. Unlike insulin or GLP-1s, most peptides require injection because they're degraded in the stomach—yet the GLP-1 experience proved Americans will self-inject if the perceived benefit justifies it. Compounded versions of GLP-1s cost around $200 versus $1,100+ for branded Ozempic, exposing a vast markup that pharmacy benefit managers historically captured.

Why it matters for you

If you're already tracking peptides on MyKine, you're part of an emerging pattern: thousands of people are obtaining compounds (tirzepatide, BPC-157, pinealon, NAD+) outside traditional prescription networks. The essay suggests this trend will accelerate, not slow. Two implications: first, the economic case for this supply chain is becoming undeniable—$200 versus $1,100 is not a rounding error—which may normalize peptide self-administration the way GLP-1 injections are normalizing now. Second, you're operating without the safety net of a doctor who knows your full picture. The essay hints at this tension: people feel better on peptide stacks but are largely unmonitored by clinicians integrated into their broader health.

The core question the piece raises is uncomfortable: if primary care were actually meeting people's needs—making them feel genuinely well, not just "normal"—would they need to go elsewhere? For MyKine users, this means your biomarkers, protocols, and self-tracking become a substitute for the continuity and comprehensiveness a good primary care doctor should provide. That's powerful for optimisation but creates blind spots if something goes wrong.

Caveats

  • Not a clinical study. This is reported narrative and opinion, not evidence about safety or efficacy of any peptide protocol.
  • Anecdotal endpoint. Delphine's experience ("lost weight, gained muscle, more energy") is a single case; we don't know her baseline, comparators, or whether effects persist.
  • Regulatory status unclear. The essay doesn't detail which peptides are actually legal to compound or how oversight works in this space.
  • Selection bias. People posting about peptide success are not representative; we hear less from those who had no effect or adverse events.
  • No discussion of long-term safety. Most of these peptides lack long-term human data outside narrow clinical indications.